Ultragenyx’s MPS IIIA Gene Therapy Application Validated by EMA on October 02, 2026 EMA etisparvovec gene therapy MAA (Microalbumin aggregate albumin) MPS Mucopolysaccharidosis Type IIIA Multiple Acyl Coenzyme A Dehydrogenase Deficiency rebisufligene Ultragenyx UX111 Validation +